Rani Therapeutics (NASDAQ:RANI) Releases Earnings Results, Misses Expectations By $0.03 EPS

Rani Therapeutics (NASDAQ:RANI - Get Free Report) issued its earnings results on Monday. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.03), Zacks reports. The business had revenue of $1.03 million for the quarter.

Rani Therapeutics Stock Performance

Shares of NASDAQ:RANI traded down $0.09 during trading on Friday, hitting $1.21. 184,819 shares of the company were exchanged, compared to its average volume of 748,422. The company has a debt-to-equity ratio of 2.34, a current ratio of 1.60 and a quick ratio of 1.60. Rani Therapeutics has a 52-week low of $1.17 and a 52-week high of $8.75. The company has a market cap of $69.32 million, a PE ratio of -1.14 and a beta of 0.14. The stock has a 50 day moving average of $1.50 and a 200 day moving average of $1.80.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on RANI. HC Wainwright reiterated a "buy" rating and issued a $9.00 price target on shares of Rani Therapeutics in a research note on Thursday. Canaccord Genuity Group reissued a "buy" rating and set a $9.00 target price on shares of Rani Therapeutics in a report on Wednesday, February 26th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $12.33.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.